World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
95
Citations
54872
World Ranking
9854
National Ranking
956

Nagahiro Saijo publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Nagahiro Saijo sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 765 publications — 85th percentile

85% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Nagahiro Saijo D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Nagahiro Saijo sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 95 D-Index — 51st percentile

51% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Nagahiro Saijo is affiliated with AstraZeneca (United Kingdom) and has contributed to research primarily in the fields of Medicine and Biochemistry, Genetics and Molecular Biology. Their scholarly work is distributed across several subfields including Pulmonary and Respiratory Medicine, Oncology, Geriatrics and Gerontology, Physiology, and Cancer Research.

Their research interests focus on topics such as Frailty in Older Adults, Nutrition and Health in Aging, Lung Cancer Diagnosis and Treatment, Renal Cell Carcinoma Treatment, Cancer Genomics and Diagnostics, and Pancreatic and Hepatic Oncology Research.

Saijo has coauthored studies with several frequent collaborators, notably Hiroshi Katayama, Junki Mizusawa, Haruhiko Fukuda, Shinichiro Nakamura, and K. Nakamura.

Their publications appear mainly in the Japanese Journal of Clinical Oncology and also in UNC Libraries, reflecting engagement with journals that focus on clinical oncology and clinical research issues.

Significant papers authored or coauthored by Saijo include:

  • Prognostic impact of geriatric assessment in elderly patients with non-small cell lung cancer: an integrated analysis of two randomized phase III trials (JCOG1115-A), 2021, Japanese Journal of Clinical Oncology
  • Real-world use of temsirolimus in Japanese patients with unresectable or metastatic renal cell carcinoma: recent consideration based on the results of a post-marketing, all-case surveillance study, 2020, Japanese Journal of Clinical Oncology
  • Japanese-US Common-Arm Analysis of Paclitaxel Plus Carboplatin in Advanced Non-Small-Cell Lung Cancer: A Model for Assessing Population-Related Pharmacogenomics, 2020, UNC Libraries

Best Publications

  • Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

    Tony S. Mok;Yi Long Wu;Sumitra Thongprasert;Chih Hsin Yang

  • International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma

    William D Travis;Elisabeth Brambilla;Masayuki Noguchi;Andrew G Nicholson

  • The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer.

    Peter Goldstraw;Kari Chansky;John Crowley;Ramon Rami-Porta

  • Irinotecan plus Cisplatin Compared with Etoposide plus Cisplatin for Extensive Small-Cell Lung Cancer

    Kazumasa Noda;Yutaka Nishiwaki;Masaaki Kawahara;Shunichi Negoro

  • Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

    Masahiro Fukuoka;Yi Long Wu;Sumitra Thongprasert;Patrapim Sunpaweravong

  • Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan

    Y Ohe;Y Ohashi;K Kubota;T Tamura

  • Phase III Study of Concurrent Versus Sequential Thoracic Radiotherapy in Combination With Cisplatin and Etoposide for Limited-Stage Small-Cell Lung Cancer: Results of the Japan Clinical Oncology Group Study 9104

    Minoru Takada;Masahiro Fukuoka;Masaaki Kawahara;Takahiko Sugiura

  • The IASLC Lung Cancer Staging Project: Proposals for Coding T Categories for Subsolid Nodules and Assessment of Tumor Size in Part-Solid Tumors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer

    William D. Travis;Hisao Asamura;Alexander A. Bankier;Mary Beth Beasley

  • Randomized Trial of Cyclophosphamide, Doxorubicin, and Vincristine Versus Cisplatin and Etoposide Versus Alternation of These Regimens in Small-Cell Lung Cancer

    Masahiro Fukuoka;Kiyoyuki Furuse;Nagahiro Saijo;Yutaka Nishiwaki

  • Phase III Study, V-15-32, of Gefitinib Versus Docetaxel in Previously Treated Japanese Patients With Non–Small-Cell Lung Cancer

    Riichiroh Maruyama;Yutaka Nishiwaki;Tomohide Tamura;Nobuyuki Yamamoto

  • Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial.

    Roy S Herbst;Yan Sun;Wilfried E E Eberhardt;Paul Germonpré

  • Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer.

    Osamu Kawai;Genichiro Ishii;Kaoru Kubota;Yukinori Murata

  • Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer

    J.-C. Soria;A. Mauguen;M. Reck;A. B. Sandler

  • Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28.

    Hironobu Minami;Kimie Sai;Mayumi Saeki;Yoshiro Saito

  • UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer.

    Kimie Sai;Mayumi Saeki;Yoshiro Saito;Shogo Ozawa

  • Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines

    Y. Kataoka;T. Mukohara;H. Shimada;N. Saijo

  • Epidermal Growth Factor Receptor Mutation Status in Circulating Free DNA in Serum: From IPASS, a Phase III Study of Gefitinib or Carboplatin/Paclitaxel in Non-small Cell Lung Cancer

    Koichi Goto;Yukito Ichinose;Yuichiro Ohe;Nobuyuki Yamamoto

  • Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301)

    Shinji Atagi;Masaaki Kawahara;Akira Yokoyama;Hiroaki Okamoto

  • The IASLC Lung Cancer Staging Project: Background Data and Proposed Criteria to Distinguish Separate Primary Lung Cancers from Metastatic Foci in Patients with Two Lung Tumors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer

    Frank C. Detterbeck;Wilbur A. Franklin;Andrew G. Nicholson;Nicolas Girard

  • The Development and Clinical Use of a Beam ON-LINE PET System Mounted on a Rotating Gantry Port in Proton Therapy

    Teiji Nishio;Aya Miyatake;Takashi Ogino;Keiichi Nakagawa

Frequent Co-Authors

Tomohide Tamura
Tomohide Tamura St. Luke's International Hospital
Yuichiro Ohe
Yuichiro Ohe National Cancer Centre
Kazuto Nishio
Kazuto Nishio Kindai University
Yutaka Nishiwaki
Yutaka Nishiwaki Tokyo Medical University
Kazuhiko Nakagawa
Kazuhiko Nakagawa Kindai University
Jun-ichi Sawada
Jun-ichi Sawada University of Shizuoka
Teruhiko Yoshida
Teruhiko Yoshida National Cancer Research Institute, UK
Yoshiro Saito
Yoshiro Saito Tohoku University
Shogo Ozawa
Shogo Ozawa Iwate Medical University
Atsushi Ohtsu
Atsushi Ohtsu Juntendo University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring online degree options can open up new routes for advancing your healthcare career or transitioning into medical fields. For nurses aiming for leadership roles, the quickest DNP program options offer a fast-track to a Doctor of Nursing Practice, balancing academic intensity with flexibility for working professionals.

If balancing clinical commitments is a concern, some candidates may prefer a DNP program without clinical hours. These programs allow students to focus more on leadership, administration, or education rather than direct patient care.

Those earlier in their nursing journey might consider fast track LPN programs, which can help students quickly gain practical nursing skills and enter the workforce. Once established, nurses with a passion for mental health can explore psych nurse practitioner programs to specialize further.

Each of these pathways provides a flexible, efficient way to enhance qualifications while managing career and personal commitments.

Best Scientists Citing Nagahiro Saijo

Trending Scientists

Recently Published Articles